HD-OPM Archive
Topics › Exercise & fitness

No drug is approved for sarcopenia; strength training and protein remain the foundation

Gokhan Can · Jul 13, 2025 · ♥ 6 reactions · 8 comments · original Facebook post
Exercise & fitnessAging & longevityProtein
AI summary & key facts

A review summary (Rolland et al., Metabolism, Dec 2023) of drug options for age-related muscle loss. No drug has regulatory approval for sarcopenia, few trials enrolled diagnosed patients, and non-drug measures remain first-line.

Sarcopenia: Can a drug fight aging associated muscle and functional loss?

#

An in-depth review by Rolland et al. from Dec 2023 in the journal Metabolism provides a sweeping analysis of the pharmacological landscape for sarcopenia, the progressive and debilitating loss of muscle mass and function associated with aging. Since its official recognition as a disease in 2016, the quest for an effective drug treatment has intensified. However, the authors reveal a field still in its infancy, where front-line treatments remain non-pharmacological—namely strength exercise and nutritional support—and no drug has yet secured regulatory approval for this specific indication.

The review meticulously outlines a fundamental challenge in sarcopenia drug development: a scarcity of clinical trials that have specifically recruited and studied patients formally diagnosed with sarcopenia. Most therapeutic trials have instead targeted broader older populations, such as men with hypogonadism or postmenopausal women, and have assessed the effects of drugs on individual components of sarcopenia—muscle mass, muscle strength, or physical performance—rather than the syndrome as a whole. This approach, coupled with a wide variety of assessment tools and endpoints across studies, has created a fragmented evidence base that makes direct comparisons and firm conclusions difficult.
Trials in Sarcopenic Patients: A Glimmer of Insight

The few randomized controlled trials (RCTs) conducted in diagnosed sarcopenic populations have yielded mixed and often underwhelming results.

Investigating Sarcopenia Components in Broader Populations

The bulk of the research has come from trials in various older populations, assessing effects on muscle health.
Hormonal Drugs

Growth Factors and Myostatin Inhibitors

Other Pharmacological Avenues

The Future of Sarcopenia Drug Treatment: A Geroscience Approach

The review concludes by looking toward the future, highlighting the Geroscience hypothesis—that by targeting the fundamental biological mechanisms of aging, we can delay or prevent multiple age-related diseases, including sarcopenia. This has opened up several innovative preclinical research avenues:

Conclusion and Recommendations for Practice

The overarching conclusion from this extensive review is that the path to a sarcopenia drug is fraught with complexity. The persistent disconnect between gains in muscle mass and improvements in physical function suggests that targeting muscle size alone is insufficient. Sarcopenia is a multifactorial syndrome, and effective treatment will likely require personalized approaches and combination therapies that may include drugs, targeted exercise, and specific nutritional interventions.

Currently, no drug should be prescribed for the indication of sarcopenia. Testosterone should be reserved for confirmed hypogonadism, and vitamin D should be supplemented only to correct a deficiency. The foundation of management remains strength and power training combined with a protein-rich diet. The future, however, is bright with possibility, as researchers move beyond single-target drugs and begin to explore therapies that address the fundamental biological drivers of aging itself.

metabolismjournal.comLink to metabolismjournal.commetabolismjournal.com

Research cited

#muscle#sarcopenia#testosterone#vitamind#aging#exercise#vitamins#inflammation
← newer: Defense of U.S. science funding and its impactolder: Sarcopenia: no drug should be prescribed; training and prote →